All sectors
Sector analysis
Pharmaceuticals & Biotechnology
Read from what its listed companies are showing. Each industry inside it is judged on its own below.
Mixed
227 listed companies · ₹ 24,94,195 Cr. total market value- ●59% of companies grew sales by more than 8% from a year earlier; the typical company's profit rose 18%. 17% made a loss.
- ▲9 credit rating upgrades and 4 downgrades in the last 90 days.
- –82 good and 12 bad company announcements, including 1 big order won (read since 6 Oct 2026; not counted until there is a month of them).
- ●The typical share is down 2% in 3 months; 55% of shares trade above their 200-day average (their usual level).
- –Typical P/E 33.2, close to these companies' usual level.
- –Raised ₹ 1,337 Cr. by issuing shares (6 issues) in 90 days; 5 more fund raises on the way.
▲ / ▼ / ● are the signals the verdict counts: results, credit ratings, announcements and share prices. Lines marked – are shown but not counted.
In charts
Share prices over the last year
The typical Pharmaceuticals & Biotechnology share against the typical share on the market, both starting at 100. Now 97 vs 83.
Is growth speeding up or slowing down?
The typical company's sales and profit growth against the same quarter a year earlier.
Industries in this sector
A sector mixes different businesses; each industry is judged on its own. Open one for its charts and companies.
| Pharmaceuticals221 companies | Improving | 60% of cos. | +18.9% | −2% | 33.2 |
| Biotechnology6 companies | Too few | 20% of cos. | −50% | −13.2% | 64.5 |
Cheaper than peers
Not a buy list. These shares trade at a P/E at least 30% below their industry's typical level and below their own usual level, and they also pass basic checks: profitable, sales and profit growing, low debt, no red flags, market value of ₹250 Cr or more. Cheap shares are often cheap for a reason; this is where to start reading, not where to stop.
| Details | |||||
|---|---|---|---|---|---|
| Sanofi India SANOFI | Pharmaceuticals | 14.4 vs 33.257% cheaper | +7.9% / +20% | ₹ 6,379.42 Cr. | |
| Lupin LUPIN | Pharmaceuticals | 14.8 vs 33.255% cheaper | +32.1% / +16.1% | ₹ 88,023.68 Cr. | |
| Anuh Pharma ANUHPHR | Pharmaceuticals | 17.4 vs 33.248% cheaper | +4.3% / +37.5% | ₹ 754.28 Cr. | |
| Bajaj Healthcare BAJAJHCARE | Pharmaceuticals | 18.1 vs 33.245% cheaper | +18.9% / +27.3% | ₹ 1,055.05 Cr. | |
| Alembic Pharmaceuticals APLLTD | Pharmaceuticals | 20 vs 33.240% cheaper | +25.7% / +11.7% | ₹ 14,927.47 Cr. | |
| Eris Lifesciences ERIS | Pharmaceuticals | 23.2 vs 33.230% cheaper | +12.9% / +14.4% | ₹ 15,246.32 Cr. | |
| Trident Lifeline 543616 | Pharmaceuticals | 23.2 vs 33.230% cheaper | +42.8% / +82.4% | ₹ 487.47 Cr. |
Cheaper than peers across the whole market
Leaders and laggards
Good news
- Onesource Specialty PharmaStrong results
- Accent MicrocellStrong results
- Bajaj HealthcareStrong results
- Glenmark PharmaceuticalsCredit rating raised
- Rubicon ResearchCredit rating raised
Warning signs
- Mangalam Drugs & Organics LtdMissed a loan payment
- Vivimed LabsInsolvency case
- Themis MedicareCredit rating cut
- Sunil HealthcareCredit rating cut
- Dr Reddy's LaboratoriesAction by a regulator
Best shares, 3 months
- Rekvina Laboratories+139.6%
- Morepen Laboratories+120.9%
- Asston Pharmaceuticals+117.5%
- Valiant Laboratories+99.8%
- Aptus Pharma+81.5%
Worst shares, 3 months
- CCME Global Ltd−73.7%
- Medico Remedies−55.7%
- Wanbury−43.4%
- Bharat Immunologicals & Biologicals Corporation Ltd−39.9%
- Kabra Drugs−37.7%
Companies
The 150 largest of 227, by market value. Click a column to sort.
| Signs (90 days) | |||||||
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries SUNPHARMA | Pharmaceuticals | ₹ 4,18,194.23 Cr. | +10.5% | +26.5% | 33.2 | −12% | |
| Divi's Laboratories DIVISLAB | Pharmaceuticals | ₹ 2,38,496.97 Cr. | +27.8% | +65.5% | 79.8 | +22.1% | |
| Torrent Pharmaceuticals TORNTPHARM | Pharmaceuticals | ₹ 1,70,474.77 Cr. | +50.8% | −9.6% | 78.5 | −5.2% | Strong results |
| Cipla CIPLA | Pharmaceuticals | ₹ 1,08,010.67 Cr. | +2.3% | −39.2% | 30.2 | −8.4% | |
| Laurus Labs LAURUSLABS | Pharmaceuticals | ₹ 1,06,657.64 Cr. | +29% | +123.5% | 97.3 | +20.2% | |
| Dr Reddy's Laboratories DRREDDY | Pharmaceuticals | ₹ 1,02,201.82 Cr. | −1.5% | −31.7% | 36.6 | +14.7% | Action by a regulator |
| Mankind Pharma MANKIND | Pharmaceuticals | ₹ 91,572.1 Cr. | +12.9% | +29% | 42.9 | −3.5% | Strong results |
| Aurobindo Pharma AUROPHARMA | Pharmaceuticals | ₹ 90,294.05 Cr. | +16.3% | +25.2% | 23.9 | +2.3% | |
| Lupin LUPIN | Pharmaceuticals | ₹ 88,023.68 Cr. | +32.1% | +16.1% | 14.8 | −20.2% | |
| Glenmark Pharmaceuticals GLENMARK | Pharmaceuticals | ₹ 60,102.56 Cr. | +23.1% | +927.7% | 19.6 | +0.2% | Credit rating raised |
| Alkem Laboratories ALKEM | Pharmaceuticals | ₹ 58,966.47 Cr. | +10.9% | −22% | 26 | −10.5% | |
| Abbott India ABBOTINDIA | Pharmaceuticals | ₹ 53,249.1 Cr. | +4.4% | +17.2% | 32.9 | −7.8% | |
| Biocon BIOCON | Pharmaceuticals | ₹ 53,225.81 Cr. | +10% | +53.9% | 72.5 | −22.9% | Action by a regulator |
| IPCA Laboratories IPCALAB | Pharmaceuticals | ₹ 49,830.22 Cr. | +20.7% | +82% | 36 | +11.7% | |
| Gland Pharma GLAND | Pharmaceuticals | ₹ 46,668.95 Cr. | +19.5% | +47.4% | 40.7 | +16% | |
| Anthem BioSciences ANTHEM | Biotechnology | ₹ 45,766.93 Cr. | −22.6% | −11.8% | 77.2 | +5.7% | |
| Ajanta Pharma AJANTPHARM | Pharmaceuticals | ₹ 41,234.14 Cr. | +24.8% | +31% | 36.1 | −0.8% | |
| GlaxoSmithKline Pharmaceuticals GLAXO | Pharmaceuticals | ₹ 40,801.04 Cr. | +16.5% | +15.6% | 38.7 | −6.7% | |
| Emcure Pharmaceuticals EMCURE | Pharmaceuticals | ₹ 33,863.35 Cr. | +22.8% | +35.8% | 32.6 | −2% | |
| Sai Life Sciences SAILIFE | Pharmaceuticals | ₹ 29,699.13 Cr. | +11.7% | +21.7% | 80.6 | +12.1% | |
| Wockhardt WOCKPHARMA | Pharmaceuticals | ₹ 29,249.67 Cr. | +25.9% | — | 73.4 | −1.7% | |
| Acutaas Chemicals ACUTAAS | Pharmaceuticals | ₹ 25,802.13 Cr. | +59.4% | +70.5% | 66.5 | +14.8% | Strong results |
| Piramal Pharma PPLPHARMA | Pharmaceuticals | ₹ 25,408.78 Cr. | +17.4% | Loss | 307.4 | +2.1% | Strong results |
| Neuland Laboratories NEULANDLAB | Pharmaceuticals | ₹ 24,132.25 Cr. | +119.1% | +957.1% | 48.8 | −2.1% | |
| Rubicon Research RUBICON | Pharmaceuticals | ₹ 23,588.3 Cr. | +51.7% | +97.7% | 81.8 | −2.5% | Credit rating raised |
| Granules India GRANULES | Pharmaceuticals | ₹ 19,620.7 Cr. | +22.1% | +59.3% | 33.4 | −1.2% | Strong results |
| Cohance Lifesciences COHANCE | Pharmaceuticals | ₹ 17,304.87 Cr. | −23.1% | Loss | 159.8 | +11.6% | |
| Caplin Point Laboratories CAPLIPOINT | Pharmaceuticals | ₹ 16,898.02 Cr. | +19.6% | +18.5% | 25.4 | −10.1% | |
| Shilpa Medicare SHILPAMED | Pharmaceuticals | ₹ 16,896.89 Cr. | +45.2% | +114.9% | 59.4 | +50.5% | |
| Pfizer PFIZER | Pharmaceuticals | ₹ 16,512.65 Cr. | +8.3% | +6.3% | 107.8 | −21.8% | |
| Alivus Life Sciences ALIVUS | Pharmaceuticals | ₹ 15,315.78 Cr. | +6.3% | +31.1% | 43.7 | +20.5% | |
| Eris Lifesciences ERIS | Pharmaceuticals | ₹ 15,246.32 Cr. | +12.9% | +14.4% | 23.2 | −16.7% | Strong results |
| Onesource Specialty Pharma ONESOURCE | Pharmaceuticals | ₹ 15,215.94 Cr. | +37.3% | — | 688.2 | −9% | Strong results |
| Alembic Pharmaceuticals APLLTD | Pharmaceuticals | ₹ 14,927.47 Cr. | +25.7% | +11.7% | 20 | −4.9% | |
| Jubilant Pharmova JUBLPHARMA | Pharmaceuticals | ₹ 14,888.24 Cr. | +17.3% | −45.1% | 38.5 | −1.9% | Expansion or acquisition |
| Natco Pharma NATCOPHARM | Pharmaceuticals | ₹ 14,189.08 Cr. | −44.7% | −57.1% | 13.6 | −14.7% | |
| Marksans Pharma MARKSANS | Pharmaceuticals | ₹ 13,008.88 Cr. | +35.6% | +174.1% | 25.1 | +15.2% | |
| Concord Biotech CONCORDBIO | Pharmaceuticals | ₹ 12,926.91 Cr. | +27.9% | +41.9% | 46.3 | +4.4% | Strong results |
| Corona Remedies CORONA | Pharmaceuticals | ₹ 12,330.08 Cr. | +21.6% | +30.4% | 59.1 | +2.3% | |
| Sudeep Pharma SUDEEPPHRM | Pharmaceuticals | ₹ 10,900.97 Cr. | +26.4% | +32.3% | 59.8 | +16.7% | Expansion or acquisition |
| Akums Drugs and Pharmaceuticals AKUMS | Pharmaceuticals | ₹ 10,639.83 Cr. | +14% | +55.4% | 34.5 | +7.6% | |
| Strides Pharma Science STAR | Pharmaceuticals | ₹ 9,269.79 Cr. | +12.9% | +55.7% | 16.1 | +2.5% | |
| Viyash Scientific Ltd VIYASH | Pharmaceuticals | ₹ 9,043.16 Cr. | +19.4% | +113.5% | 40.6 | −16.7% | |
| Blue Jet Healthcare BLUEJET | Pharmaceuticals | ₹ 8,979.24 Cr. | −17.5% | −14.3% | 38.3 | −17.4% | |
| Procter & Gamble Health PGHL | Pharmaceuticals | ₹ 8,377.19 Cr. | +7.4% | +45.5% | 25 | −15.5% | |
| Symbiotec Pharmalab Ltd SYMBIOTEC | Pharmaceuticals | ₹ 7,517.7 Cr. | — | — | 64.9 | — | |
| Aarti Pharmalabs AARTIPHARM | Pharmaceuticals | ₹ 7,420.89 Cr. | +38.9% | +52% | 34.6 | +29.6% | |
| Sanofi Consumer Healthcare India SANOFICONR | Pharmaceuticals | ₹ 7,413.13 Cr. | +6.8% | +13.1% | 27.8 | −27.8% | |
| Morepen Laboratories MOREPENLAB | Pharmaceuticals | ₹ 6,753.53 Cr. | +34.1% | +409.1% | 57.5 | +120.9% | Strong results |
| Bliss GVS Pharma BLISSGVS | Pharmaceuticals | ₹ 6,640.06 Cr. | +38.2% | +15.9% | 48.6 | +40.3% | Promoters buying |
| Supriya Lifescience SUPRIYA | Pharmaceuticals | ₹ 6,590.74 Cr. | +31% | −31.4% | 33.1 | −0.9% | |
| Sanofi India SANOFI | Pharmaceuticals | ₹ 6,379.42 Cr. | +7.9% | +20% | 14.4 | −9.7% | |
| Innova Captab INNOVACAP | Pharmaceuticals | ₹ 5,622.98 Cr. | +33.8% | +41.9% | 36.7 | +10.4% | Credit rating raised |
| Senores Pharmaceuticals SENORES | Pharmaceuticals | ₹ 5,600.1 Cr. | +30.4% | +42.9% | 44.3 | −0.7% | |
| Novartis India NOVARTIND | Pharmaceuticals | ₹ 4,530.14 Cr. | +18.2% | +14.3% | 46.3 | +15.4% | |
| RPG Life Sciences RPGLIFE | Pharmaceuticals | ₹ 4,325.38 Cr. | +16% | +19.2% | 37 | 0% | |
| Zota Health Care ZOTA | Pharmaceuticals | ₹ 4,298.25 Cr. | +67.3% | Loss | 327 | +3.7% | |
| Gujarat Themis Biosyn GUJTHEM | Pharmaceuticals | ₹ 4,233.82 Cr. | +22.2% | +22.2% | 87.5 | −1.1% | |
| Orchid Pharma ORCHPHARMA | Pharmaceuticals | ₹ 4,153.09 Cr. | +15.6% | — | 273.9 | −16.2% | |
| Gufic BioSciences GUFICBIO | Pharmaceuticals | ₹ 3,935.74 Cr. | +15% | +83.3% | 53.6 | +9.3% | Action by a regulator |
| SMS Pharmaceuticals SMSPHARMA | Pharmaceuticals | ₹ 3,876.49 Cr. | +5.6% | +5% | 37.9 | +12.2% | Rating outlook cut |
| Kwality Pharmaceuticals KPL | Pharmaceuticals | ₹ 3,735.12 Cr. | +45.9% | +116.7% | 44.9 | +38.9% | |
| Aarti Drugs AARTIDRUGS | Pharmaceuticals | ₹ 3,442.27 Cr. | +19% | −7.4% | 17.7 | −1.9% | |
| Unichem Laboratories UNICHEMLAB | Pharmaceuticals | ₹ 3,280.49 Cr. | +20.1% | — | 27.2 | −10% | |
| Solara Active Pharma Sciences SOLARA | Pharmaceuticals | ₹ 2,956.93 Cr. | +32.8% | — | 62.7 | +25.8% | Strong results |
| Shukra Pharmaceuticals SHUKRAPHAR | Pharmaceuticals | ₹ 2,826.75 Cr. | +380% | +1,400% | 84.1 | — | Promoters buying |
| Advanced Enzyme Technologies ADVENZYMES | Biotechnology | ₹ 2,779.25 Cr. | +2.2% | −2.5% | 17.6 | −16.2% | Share buyback |
| Hikal HIKAL | Pharmaceuticals | ₹ 2,382.95 Cr. | +5.9% | Loss | 56.6 | −8.4% | |
| Fredun Pharmaceuticals FREDUN | Pharmaceuticals | ₹ 2,241.86 Cr. | +90% | +85.7% | 51.6 | — | |
| Dishman Carbogen Amcis DCAL | Pharmaceuticals | ₹ 2,134.6 Cr. | −4.2% | Loss | 117.8 | −21.8% | |
| Beta Drugs BETA | Pharmaceuticals | ₹ 2,100.33 Cr. | +33% | +58.3% | 40.5 | −12.5% | |
| Sai Parenterals Ltd SAIPARENT | Pharmaceuticals | ₹ 2,003.87 Cr. | — | — | 143 | −12.9% | |
| Syncom Formulations India Ltd SYNCOMF | Pharmaceuticals | ₹ 1,993.13 Cr. | +6.8% | +56.3% | 23.3 | +56.7% | |
| Sakar Healthcare SAKAR | Pharmaceuticals | ₹ 1,953.1 Cr. | +50% | +120% | 46.2 | +10.1% | Strong results |
| Panacea Biotec PANACEABIO | Pharmaceuticals | ₹ 1,917.15 Cr. | +19.7% | −44.4% | 4.5 | −24.5% | |
| Venus Remedies VENUSREM | Pharmaceuticals | ₹ 1,906.9 Cr. | +30.7% | +130% | 16.1 | +12.6% | Strong results |
| Windlas Biotech WINDLAS | Pharmaceuticals | ₹ 1,859 Cr. | +18.1% | 0% | 27.1 | +2.3% | |
| Hester Biosciences HESTERBIO | Pharmaceuticals | ₹ 1,729.7 Cr. | −8.3% | +470.6% | 32.8 | −12.3% | Credit rating raised |
| NGL Fine Chem Ltd NGLFINE | Pharmaceuticals | ₹ 1,632.48 Cr. | +35.6% | +100% | 28.6 | −19.7% | |
| Accent Microcell ACCENTMIC | Pharmaceuticals | ₹ 1,424.95 Cr. | +38.9% | +93.8% | 25 | +30.1% | Strong results |
| Amrutanjan Health Care AMRUTANJAN | Pharmaceuticals | ₹ 1,421.81 Cr. | +9.5% | −47.4% | 69.2 | −5.4% | |
| Jagsonpal Pharmaceuticals JAGSNPHARM | Pharmaceuticals | ₹ 1,401.8 Cr. | +7.9% | +18.2% | 29.7 | −2.6% | |
| Anlon Healthcare AHCL | Pharmaceuticals | ₹ 1,358.55 Cr. | +78.9% | −50.3% | 47.6 | +53.4% | |
| Fermenta Biotech FERMENTA | Pharmaceuticals | ₹ 1,342.35 Cr. | −10.6% | −55.9% | 24.5 | −2.1% | Credit rating raised |
| Kopran KOPRAN | Pharmaceuticals | ₹ 1,179.04 Cr. | +13.9% | −10.1% | 47.8 | +29.8% | |
| Bharat Parenterals BPLPHARMA | Pharmaceuticals | ₹ 1,140.62 Cr. | −19.2% | Loss | 50.8 | — | |
| Bafna Pharmaceuticals BAFNAPH | Pharmaceuticals | ₹ 1,064.19 Cr. | −23.2% | −97.6% | 33.9 | +75.2% | |
| Bajaj Healthcare BAJAJHCARE | Pharmaceuticals | ₹ 1,055.05 Cr. | +18.9% | +27.3% | 18.1 | −4.6% | Strong results |
| Remus Pharmaceuticals REMUS | Pharmaceuticals | ₹ 1,042.88 Cr. | +144.9% | +31.6% | 28.1 | +23.1% | |
| Lincoln Pharmaceuticals LINCOLN | Pharmaceuticals | ₹ 1,034.4 Cr. | +14.9% | +28.6% | 10.7 | −4.9% | |
| Sigachi Industries SIGACHI | Pharmaceuticals | ₹ 964.75 Cr. | −5.4% | — | 42.7 | +1.3% | |
| Aptus Pharma 544529 | Pharmaceuticals | ₹ 842.92 Cr. | — | — | 106 | +81.5% | |
| Themis Medicare THEMISMED | Pharmaceuticals | ₹ 826.24 Cr. | −11.2% | — | 36.1 | −11.4% | Credit rating cut |
| Shree Ganesh Remedies SGRL | Pharmaceuticals | ₹ 803.74 Cr. | −41.8% | −67.5% | 52 | — | |
| Anuh Pharma ANUHPHR | Pharmaceuticals | ₹ 754.28 Cr. | +4.3% | +37.5% | 17.4 | +1.1% | |
| Valiant Laboratories VALIANTLAB | Pharmaceuticals | ₹ 701.99 Cr. | +144.7% | +950% | 43.6 | +99.8% | |
| ZIM Laboratories ZIMLAB | Pharmaceuticals | ₹ 663.09 Cr. | +31.2% | Loss | 158.9 | +17.4% | Rating outlook cut |
| Amanta Healthcare AMANTA | Pharmaceuticals | ₹ 629.23 Cr. | +5.3% | −5.7% | 41.3 | +12.6% | |
| Wanbury WANBURY | Pharmaceuticals | ₹ 623.1 Cr. | +1.5% | −76% | 14.5 | −43.4% | |
| Influx Healthtech INFLUX | Pharmaceuticals | ₹ 594.97 Cr. | — | — | 31.1 | −14.1% | |
| Transchem 500422 | Pharmaceuticals | ₹ 511.63 Cr. | — | +245.5% | 76.3 | +30% | |
| KRM Ayurveda KRMAYURVED | Pharmaceuticals | ₹ 507.71 Cr. | — | — | 25.2 | −10.4% | |
| Trident Lifeline 543616 | Pharmaceuticals | ₹ 487.47 Cr. | +42.8% | +82.4% | 23.2 | +64% | |
| Haleos Labs HALEOSLABS | Pharmaceuticals | ₹ 480.46 Cr. | −11.6% | −58.1% | 28.7 | −5.8% | |
| Infinium Pharmachem INFINIUM | Pharmaceuticals | ₹ 445.68 Cr. | +43.2% | +60% | 36.7 | +38.1% | |
| Albert David ALBERTDAVD | Pharmaceuticals | ₹ 431.46 Cr. | +42.3% | +300% | 19.1 | +13.2% | |
| Jenburkt Pharmaceuticals JENBURPH | Pharmaceuticals | ₹ 375.51 Cr. | −0.1% | −24.4% | 10.6 | — | |
| Medicamen Biotech MEDICAMEQ | Pharmaceuticals | ₹ 349.18 Cr. | +11.3% | +15.6% | 31.8 | +10.8% | |
| Astonea Labs 544409 | Pharmaceuticals | ₹ 339.5 Cr. | — | — | 75.1 | +18% | |
| Lyka Labs LYKALABS | Pharmaceuticals | ₹ 302.01 Cr. | +28.1% | +107.1% | 127 | +32% | |
| Aarey Drugs & Pharmaceuticals Ltd AAREYDRUGS | Pharmaceuticals | ₹ 295.59 Cr. | −56.3% | −25.5% | 81 | +40.2% | |
| Astal Laboratories 512600 | Pharmaceuticals | ₹ 281.23 Cr. | — | — | 19 | −20.3% | |
| Ambalal Sarabhai Enterprises AMBALALSA | Pharmaceuticals | ₹ 263.84 Cr. | +8% | −51.6% | 18.6 | +14% | |
| BDH Industries 524828 | Pharmaceuticals | ₹ 246 Cr. | +20.2% | +48.6% | 20.8 | −25.5% | |
| Zenotech Laboratories 532039 | Pharmaceuticals | ₹ 244.11 Cr. | +10.2% | Loss | 408.7 | −13.5% | |
| Everest Organics 524790 | Pharmaceuticals | ₹ 216.11 Cr. | −10% | −21.3% | 42.2 | −14.6% | |
| Accretion Nutraveda Ltd 544694 | Pharmaceuticals | ₹ 209.96 Cr. | — | — | 39 | −4.3% | |
| Sat Kartar Life SATKARTAR | Pharmaceuticals | ₹ 205.39 Cr. | +39.5% | +125% | 13.1 | +3.9% | Strong results |
| Accretion Pharmaceuticals ACCPL | Pharmaceuticals | ₹ 202.42 Cr. | +243.7% | +230.2% | 20.9 | +12.1% | |
| Nectar Lifesciences NECLIFE | Pharmaceuticals | ₹ 199.73 Cr. | −100% | Loss | 17.6 | +3.4% | |
| Gennex Laboratories 531739 | Pharmaceuticals | ₹ 197.88 Cr. | +16.6% | −6.8% | 11.2 | +0.9% | |
| Sanjivani Paranteral 531569 | Pharmaceuticals | ₹ 192.86 Cr. | +8.8% | +32.9% | 25.2 | +1.6% | |
| Bio Medica Laboratories BMLL | Pharmaceuticals | ₹ 188.63 Cr. | — | — | 16.1 | −2.3% | |
| Coral Laboratories 524506 | Pharmaceuticals | ₹ 176.48 Cr. | +57.4% | +110.5% | 9.3 | −11.8% | |
| Brooks Laboratories BROOKS | Pharmaceuticals | ₹ 171.51 Cr. | −10% | Loss | 12.9 | −0.7% | |
| Oxygenta Pharmaceutical 524636 | Pharmaceuticals | ₹ 170.39 Cr. | +144.5% | Loss | 16.3 | −4.5% | |
| Kerala Ayurveda 530163 | Pharmaceuticals | ₹ 169.12 Cr. | +16% | Loss | 346 | −5.5% | |
| Syschem India Ltd 531173 | Pharmaceuticals | ₹ 168.89 Cr. | −0.1% | Loss | 27.1 | −13.6% | |
| Achyut Healthcare 543499 | Pharmaceuticals | ₹ 165.06 Cr. | +1.3% | +40% | 525 | +10.9% | |
| Medico Remedies MEDICO | Pharmaceuticals | ₹ 164.31 Cr. | +81.4% | +38.5% | 12.1 | −55.7% | |
| Natural Capsules NATCAPSUQ | Pharmaceuticals | ₹ 162.49 Cr. | +7.8% | Loss | 194.3 | −0.4% | |
| Smruthi Organics 540686 | Pharmaceuticals | ₹ 154.94 Cr. | +55.4% | — | 19.2 | +16.2% | |
| Gujarat Inject Kerala 524238 | Pharmaceuticals | ₹ 145.02 Cr. | +414.5% | +1,685.7% | 48.1 | −0.5% | |
| Curis Lifesciences CURIS | Pharmaceuticals | ₹ 143.09 Cr. | — | — | 20.6 | +60.7% | |
| Kimia Biosciences 530313 | Pharmaceuticals | ₹ 141.48 Cr. | −12.1% | −40% | 19.7 | −3% | |
| CCME Global Ltd 514336 | Biotechnology | ₹ 136.74 Cr. | — | Loss | 66.4 | −73.7% | |
| Quest Laboratories QUESTLAB | Pharmaceuticals | ₹ 134.38 Cr. | −30.2% | +47.9% | 9 | −13.7% | |
| Auro Laboratories 530233 | Pharmaceuticals | ₹ 134.1 Cr. | +216.6% | — | 71.9 | −0.5% | |
| Bal Pharma BALPHARMA | Pharmaceuticals | ₹ 130.86 Cr. | +34.5% | +438.1% | 18 | −10.2% | |
| Par Drugs and Chemicals PAR | Pharmaceuticals | ₹ 129.19 Cr. | +6.4% | −86.9% | 8.8 | +14.2% | |
| Parnax Lab PARNAXLAB | Pharmaceuticals | ₹ 128.47 Cr. | +6.4% | −86.9% | 12.8 | — | |
| Panchsheel Organics 531726 | Pharmaceuticals | ₹ 127.35 Cr. | +4.7% | −18.9% | 12.4 | −14% | |
| Lactose India Ltd 524202 | Pharmaceuticals | ₹ 125.2 Cr. | +18.7% | +58% | 18.1 | −3.9% | |
| Speciality Medicines 544738 | Pharmaceuticals | ₹ 123.88 Cr. | — | — | 9.6 | −24.5% | |
| Godavari Drugs 530317 | Pharmaceuticals | ₹ 122.04 Cr. | +17.4% | +6.7% | 33.8 | +10.1% | |
| Makers Laboratories MAKERSL | Pharmaceuticals | ₹ 113.29 Cr. | +22.2% | +255.8% | 33.2 | — | |
| Balaxi Pharmaceuticals BALAXI | Pharmaceuticals | ₹ 111.76 Cr. | +14.1% | +348.3% | 47.5 | −15.9% | |
| Asston Pharmaceuticals 544445 | Pharmaceuticals | ₹ 110.76 Cr. | — | — | 36.2 | +117.5% | |
| Tyche Industries 532384 | Pharmaceuticals | ₹ 106.65 Cr. | −28.3% | Loss | 24 | −16.5% | |
| Alpa Laboratories ALPA | Pharmaceuticals | ₹ 103.31 Cr. | +25.2% | −91.7% | 25.6 | −22.7% |
Figures are medians and shares of companies, so one giant company cannot outweigh the rest. Results compare each company's latest quarter with the same quarter a year earlier; ratings and announcements cover the last 90 days (announcements are read by AI and can be wrong). This page adds up published data; it is not a recommendation to buy or sell anything.